Tumor Lysis Syndrome as a Consequence of Chronic Lymphocytic Leukemia Treatment With Fludarabine and Rituximab

Yazigi,

doi:10.4021/jmc239w

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor lysis syndrome (TLS) is an oncological emergency [2] which Cairo and Bishop have classified it into two groups; namely Laboratory Tumor Lysis Syndrome and Clinical Tumor Lysis Syndrome [3] (Table 2). It is most commonly seen after the initiation of chemotherapy in hematological malignancies such as Burkitt's lymphoma, Acute Lymphoblastic Leukemias [4]. TLS can progress to acute kidney failure because of urate nephropathy [5], ARDS [6], seizures or even sudden death due to cardiac arrhythmias [1].…”

Section: Discussionmentioning

confidence: 99%

Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Small Cell Carcinoma of the Lung

Padhi¹,

Singh²

2012

JCST

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a life-threatening condition which could result in electrolyte imbalances, acute renal failure, seizures, arrhythmias and sudden death. It is mostly seen after the initiation of chemotherapy in hematological malignancies such as Burkitt's lymphoma and other Non-Hodgkin's Lymphoma. Solid tumors are rarely associated with Tumor Lysis Syndrome. TLS prior to the initiation of chemotherapy is known as spontaneous TLS, of which most of the literature involves hematological malignancies. There have been only a handful of case reports of spontaneous TLS occurring in solid tumors. We are presenting a patient who was newly diagnosed with metastatic small cell cancer of lung who developed spontaneous TLS. To our knowledge this is the first reported case of spontaneous TLS in small cell cancer of the lung. We will also review the literature on spontaneous TLS in solid tumors and whether as clinicians we can identify high-risk patients. Prompt diagnosis is essential in order to initiate necessary prophylactic precautions. After reviewing the few case reports it appears bulky tumors, site of metastases, prior renal functions may predict risk of suffering from TLS in solid tumors.

show abstract